{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:28:59Z","timestamp":1784734139647,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006474","name":"Columbia University","doi-asserted-by":"publisher","award":["UL1 RR024156"],"award-info":[{"award-number":["UL1 RR024156"]}],"id":[{"id":"10.13039\/100006474","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.pbb.2024.173918","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T11:55:04Z","timestamp":1732881304000},"page":"173918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Venlafaxine treatment is associated with improved mood, but not decreased cocaine self-administration, in depressed people who use cocaine"],"prefix":"10.1016","volume":"247","author":[{"given":"Rebecca L.","family":"Chalm\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette M.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Haney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Foltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pbb.2024.173918_bb0005","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/00952990.2011.644002","article-title":"The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression","volume":"38","author":"Afshar","year":"2012","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"3","key":"10.1016\/j.pbb.2024.173918_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.drugalcdep.2005.07.009","article-title":"A randomized placebo-controlled trial of gabapentin for cocaine dependence","volume":"81","author":"Bisaga","year":"2006","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.pbb.2024.173918_bb0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1176\/ajp.155.2.220","article-title":"Depression among cocaine abusers in treatment: relation to cocaine and alcohol use and treatment outcome","volume":"155","author":"Brown","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173918_bb5000","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1360-0443.2005.00984.x","article-title":"Nefazodone treatment of cocaine dependence with depressive symptoms","volume":"100","author":"Ciraulo","year":"2005","journal-title":"Addiction"},{"issue":"1\u20133","key":"10.1016\/j.pbb.2024.173918_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.drugalcdep.2009.02.004","article-title":"Cardiovascular and subjective effects of repeated smoked cocaine administration in experienced cocaine users","volume":"102","author":"Collins Reed","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"02","key":"10.1016\/j.pbb.2024.173918_bb0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.v67n0211","article-title":"Lifetime comorbidity of dsm-iv mood and anxiety disorders and specific drug use disorders","volume":"67","author":"Conway","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2024.173918_bb0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","article-title":"Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments","volume":"102","author":"Duman","year":"2019","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.pbb.2024.173918_bb0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review update","volume":"81","author":"Evoy","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.pbb.2024.173918_bb5005","first-page":"241","article-title":"Cocaine self-administration in humans","volume":"41","author":"Fischman","year":"1982","journal-title":"Fed. Proc."},{"issue":"2","key":"10.1016\/j.pbb.2024.173918_bb0040","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1037\/1064-1297.11.2.123","article-title":"The effects of venlafaxine on the subjective, reinforcing, and cardiovascular effects of cocaine in opioid-dependent and non-opioid-dependent humans","volume":"11","author":"Foltin","year":"2003","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2024.173918_bb0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2005.03.006","article-title":"Smoked cocaine discrimination in humans: effects of gabapentin","volume":"80","author":"Haney","year":"2005","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"10.1016\/j.pbb.2024.173918_bb0050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.drugalcdep.2003.10.015","article-title":"Gabapentin maintenance decreases smoked cocaine-related subjective effects, but not self-administration by humans","volume":"73","author":"Hart","year":"2004","journal-title":"Drug Alcohol Depend."},{"issue":"2\u20133","key":"10.1016\/j.pbb.2024.173918_bb0055","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.drugalcdep.2006.05.028","article-title":"Smoked cocaine self-administration by humans is not reduced by large gabapentin maintenance doses","volume":"86","author":"Hart","year":"2007","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.pbb.2024.173918_bb0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/FBP.0b013e328014139d","article-title":"Gabapentin does not reduce smoked cocaine self-administration: employment of a novel self-administration procedure","volume":"18","author":"Hart","year":"2007","journal-title":"Behav. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2024.173918_bb0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/archpsyc.59.4.375","article-title":"Effects of major depression on remission and relapse of substance dependence","volume":"59","author":"Hasin","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2024.173918_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/00952999209001609","article-title":"Retention of cocaine abusers in outpatient psychotherapy","volume":"18","author":"Kleinman","year":"1992","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"7","key":"10.1016\/j.pbb.2024.173918_bb0075","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/npp.2008.236","article-title":"Metabotropic glutamate receptor 7 modulates the rewarding effects of cocaine in rats: involvement of a ventral pallidal GABAergic mechanism","volume":"34","author":"Li","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2024.173918_bb0080","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/mp.2010.120","article-title":"The GABAergic deficit hypothesis of major depressive disorder","volume":"16","author":"L\u00fcscher","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2024.173918_bb0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/JCP.0000000000000062","article-title":"Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms","volume":"34","author":"Mancino","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2024.173918_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1081\/ADA-100100588","article-title":"Venlafaxine treatment of cocaine abusers with depressive disorders","volume":"26","author":"McDowell","year":"2000","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"2","key":"10.1016\/j.pbb.2024.173918_bb0095","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.drugalcdep.2005.03.026","article-title":"Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial","volume":"80","author":"McDowell","year":"2005","journal-title":"Drug Alcohol Depend."},{"issue":"s6","key":"10.1016\/j.pbb.2024.173918_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1157.1999.tb00932.x","article-title":"Gabapentin in the management of convulsive disorders","volume":"40","author":"McLean","year":"1999","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.pbb.2024.173918_bb0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1360-0443.2011.03552.x","article-title":"Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms","volume":"107","author":"Oliveto","year":"2011","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.pbb.2024.173918_bb0110","first-page":"356","article-title":"Current status of co-occurring mood and substance use disorders: a new therapeutic target","volume":"13","author":"Pettinati","year":"2015","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pbb.2024.173918_bb0115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1521-0391.2013.12065.x","article-title":"A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients","volume":"23","author":"Raby","year":"2013","journal-title":"Am. J. Addict."},{"issue":"1","key":"10.1016\/j.pbb.2024.173918_bb0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archpsyc.1991.01810250045005","article-title":"Psychiatric diagnoses of treatment-seeking cocaine abusers","volume":"48","author":"Rounsaville","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.pbb.2024.173918_bb0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10550490701389880","article-title":"Early abstinence in cocaine dependence: influence of comorbid major depression","volume":"16","author":"Rubin","year":"2007","journal-title":"Am. J. Addict."},{"issue":"3","key":"10.1016\/j.pbb.2024.173918_bb0130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0376-8716(00)00208-8","article-title":"Fluoxetine treatment of cocaine-dependent patients with major depressive disorder","volume":"63","author":"Schmitz","year":"2001","journal-title":"Drug Alcohol Depend."},{"issue":"10","key":"10.1016\/j.pbb.2024.173918_bb0135","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1111\/j.1460-9568.2008.06479.x","article-title":"Cocaine disinhibits dopamine neurons in the ventral tegmental area via use-dependent blockade of GABA neuron voltage-sensitive sodium channels","volume":"28","author":"Steffensen","year":"2008","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.pbb.2024.173918_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109054","article-title":"Citalopram for treatment of cocaine use disorder: a Bayesian drop-the-loser randomized clinical trial","volume":"228","author":"Suchting","year":"2021","journal-title":"Drug Alcohol Depend."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724002120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724002120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:19:34Z","timestamp":1769505574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305724002120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"alternative-id":["S0091305724002120"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173918","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venlafaxine treatment is associated with improved mood, but not decreased cocaine self-administration, in depressed people who use cocaine","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"173918"}}